BioBusiness

A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts.

Pharmaceutical Technology spoke with Tommy Fanning, head of biopharmaceuticals for IDA Ireland, to get a perspective on how Brexit may affect the pharmaceutical industry.

Reducing regulatory roadblocks requires more than the stroke of a pen.

Report: Global medicine spending will reach nearly $1.5 trillion by 2021.

Questions about new healthcare policies, investments, drug approvals, and more will test Biopharma.

What will manufacturers have to do to ensure the continued uptake of biosimilars?

Rookie API developers beat pharma at its own game.

Job security may have increased, but biopharma professionals remain somewhat dissatisfied with pay levels.

What’s ahead for the healthcare and pharmaceutical industries?

Value assessment initiatives are expected to have a major impact on drug use and reimbursement.

Steep price increases for a popular drug have created patient and Congressional backlash.

A KPMG survey reveals that approximately 84% of pharma and medical device executives plan to add jobs in next 12 months.

Congressional partisanship creates noise, but no funding for Zika virus research.

CPhI Pharma Awards seek nominations for excellence in biopharma development and manufacturing.

Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.

Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.

Insight on the new regulatory framework from the China Food and Drug Administration

BioPharm sat down with an intellectual property lawyer to examine how companies are protected when they engage in activities where sharing of trade secrets must occur.

Policies for patient access to life-saving therapies must keep pace with biomedical innovation.

Immuno-oncology drugs are demonstrating patient benefits, but growing resistant to the high cost has implications for patients, market access, and manufacturers.

Thought leaders tackle drug shortages and biomanufacturing challenges.

Report: Biologics contribute to rebirth of biopharma innovation.

Infrastructure and payer decisions will determine drug choices in emerging and developed regions.

Corporate restructurings, regulatory initiatives, and biosimilars will shape biopharma development in 2016.